Clarivate Plc filings document the financial reporting, governance and capital structure of a Jersey-incorporated public company that provides enriched data, analytics, workflow solutions and expert services across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Current reports furnish quarterly and annual earnings releases, supplemental revenue, earnings and guidance materials, and Regulation FD presentations.
The company's SEC records also cover proxy governance and executive compensation matters, including annual meeting disclosures and executive severance plan terms. Other filings describe financing arrangements involving subsidiaries, credit agreement amendments, senior secured note redemption and satisfaction and discharge, and related material-event disclosures under the Exchange Act.
Clarivate Plc (CLVT) completed the sale of its Life Sciences and Healthcare (LS&H) business on October 6, 2026, for an aggregate purchase price of $600 million: approximately $500 million cash at closing, a $75.0 million unsecured senior note and $25.0 million deferred cash consideration. Clarivate received approximately $488.4 million at closing, net of closing costs and working-capital adjustments. LS&H is classified as discontinued operations in the third quarter of 2026.
Pro forma continuing-operations revenue was $990.8 million and net loss was $79.6 million for the six months ended June 30, 2026; for the year ended December 31, 2025, revenue was $2,065.4 million and net loss was $172.1 million. The illustrative statements include transition services Clarivate will provide to Altaris for one to 12 months after closing; Clarivate cautions actual results may differ significantly.
Financing adjustments reflect anticipated use of $488.4 million in closing proceeds and $11.6 million of company cash for partial redemptions of 2028 Senior Secured and 2029 Senior Notes, plus company cash used in September 2026 for a $75.0 million tender offer for 2028 Senior Secured Notes. Pro forma long-term debt is $3,634.3 million, with a $575.0 million financing adjustment.
Clarivate plc (CLVT) reported that its President, LS&H, Henry Levy, had 263,576 ordinary shares withheld on October 6, 2026, for taxes due upon vesting of restricted share units. The reported price was $1.47 per share. After the transaction, he directly held 719,797 ordinary shares.
Clarivate Plc completed the sale of its Life Sciences & Healthcare business to an affiliate of Altaris, LLC on October 6, 2026. The transaction was announced at $600 million. At closing, the buyer paid $500 million in cash, subject to customary adjustments for cash, indebtedness, working capital and transaction expenses, and an affiliate of the buyer issued a $75 million unsecured senior note to a wholly owned Clarivate subsidiary. A further $25 million in deferred consideration is payable on the latest of specified transition-services and final-payment milestones and January 31, 2028, but no later than January 31, 2028.
Clarivate said it intends to use the transaction proceeds to reduce debt and strengthen its balance sheet. Henry Levy, Clarivate’s President, Life Sciences & Healthcare, terminated employment with a subsidiary upon closing; a separation agreement provides for payments and benefits under his retention agreement. Clarivate expects to file unaudited pro forma financial statements by October 13, 2026, and plans to report third-quarter results on November 3, 2026, with full-year 2026 guidance updated to reflect the divestiture.
Clarivate plc director Kenneth L. Cornick was granted 17,215 ordinary shares on September 30, 2026, as a quarterly award elected in lieu of a $28,750 cash retainer. The share count was calculated using $1.67, the closing price that day. On the same date, 3,444 shares were withheld for taxes. Cornick also reported indirect ownership of 2,000,000 ordinary shares held by Cornick Family Investor, LLC; Cornick and his spouse, as the LLC’s managers, have voting and dispositive control over those shares.
Clarivate Plc director Jane L. Okun Bomba received a quarterly award of 17,215 ordinary shares on September 30, 2026, elected in lieu of a $28,750 cash retainer for board service. The award was granted under the Clarivate Plc Amended and Restated 2019 Incentive Award Plan, and 181 shares were withheld for taxes. As of September 30, 2026, Jane Okun Bomba Trust U/A DTD 12/20/2018 held 49,750 ordinary shares indirectly.
Clarivate Plc director Andrew Miles Snyder received a quarterly award of 30,688 ordinary shares on September 30, 2026, elected in lieu of a $51,250 cash retainer for board service. The award share count was calculated using $1.67, the closing price that day. The report also records 1,012 ordinary shares withheld for taxes.
Separately, indirect holdings as of September 30, 2026, were reported as 6,819,742 ordinary shares by Cambridge Information Group Inc.; 2,247,510 by Cambridge Information Group I LLC; 10,178,764 by Cambridge Information Group II LLC; 3,856,597 by Cambridge Information Group III LLC; 3,417 by CSA GP Corporation; and 238,500 by Snyder 2011 Family Trust. Cambridge Information Group Inc. manages the three LLCs, and CSA GP Corporation is its wholly owned subsidiary. Snyder disclaimed beneficial ownership except to the extent of his pecuniary interest; the notes identify him as a Cambridge Information Group Inc. CEO and shareholder and as a trustee and beneficiary of the trust.
CLARIVATE PLC announced final results of its wholly owned subsidiary Clarivate Science Holdings Corporation’s cash tender offer for its 3.875% Senior Secured Notes due 2028, which sought up to $75,000,000 in aggregate principal. Of $665,198,000 in aggregate principal tendered, $75,000,000 was accepted, with an 11.3% proration factor. The notes had $825,000,000 in aggregate principal outstanding before the offer.
All offer conditions were satisfied or waived by the September 23, 2026 expiration. Settlement is set for September 25, 2026, when holders whose notes were accepted will also receive an Accrued Coupon Payment. Notes not accepted will be returned promptly to tendering holders.
CLARIVATE PLC announced pricing terms for a cash tender offer by its wholly owned subsidiary, Clarivate Science Holdings Corporation, for its 3.875% Senior Secured Notes due 2028. The offer has a $75,000,000 aggregate-principal cap, subject to proration and other conditions. The stated Total Consideration is $975.15 per $1,000 principal amount validly tendered for purchase, plus accrued and unpaid interest for notes accepted. The notes had $825,000,000 in aggregate principal amount outstanding.
The pricing uses a 4.864% Reference Yield and a +50-basis-point Fixed Spread. The offer expires at 5:00 p.m. New York City time on September 23, 2026, unless extended or earlier terminated. The subsidiary may change the Tender Cap before expiration and may accept up to 2% more of the outstanding notes without amending or extending the offer. Settlement was expected September 25, 2026.
Clarivate Plc (CLVT) announced that its wholly owned subsidiary, Clarivate Science Holdings Corporation, has commenced a cash tender offer for a portion of its 3.875% Senior Secured Notes due 2028. The offer is capped at $75,000,000 aggregate principal amount of notes, subject to proration and other terms in the Offer to Purchase.
The notes have $825,000,000 aggregate principal amount outstanding, with a maturity date of July 1, 2028. The Total Consideration per $1,000 principal will be based on a fixed spread of 50 basis points over the yield of the 4.125% U.S. Treasury due June 30, 2028, determined on September 23, 2026. The offer is scheduled to expire at 5:00 p.m. New York City time on September 23, 2026, with settlement expected on September 25, 2026, and includes payment of accrued and unpaid interest on accepted notes.
CLARIVATE PLC (CLVT) reported that a senior officer received an equity award. On 2026-08-15, the Senior VP and CAO, as the reporting person, was granted 67,357 Ordinary Shares at a price of $0.00 per share as a grant or award acquisition. Following this award, the reporting person directly holds 147,255 Ordinary Shares.